SECOND AMENDMENT TO PURCHASE AND SALE AGREEMENTPurchase and Sale Agreement • December 28th, 2018 • Recro Pharma, Inc. • Pharmaceutical preparations
This Second Amendment to Purchase and Sale Agreement (this “Amendment”), dated December 20, 2018 (the “Amendment Effective Date”) by and among Alkermes Pharma Ireland Limited, a private company limited by shares and incorporated in Ireland (“APIL”), Daravita Limited, a private company limited by shares and incorporated in Ireland (“Daravita”), Alkermes US Holdings, Inc. (as successor in interest to Eagle Holdings USA, Inc.), a Delaware corporation (together with APIL, “Sellers”), Recro Pharma, Inc., a Pennsylvania corporation (“Recro”) and Recro Gainesville LLC (as successor to Recro Pharma LLC), a Massachusetts limited liability company and wholly-owned subsidiary of Recro (“Recro Gainesville” and, together with Recro, “Purchasers”), amends that certain Purchase and Sale Agreement, dated as of March 7, 2015 and amended on December 8, 2016, by and among Sellers, Daravita and Purchasers (as amended, the “Agreement”).
SECOND AMENDMENT TO ASSET TRANSFER AND LICENSE AGREEMENTAsset Transfer and License Agreement • December 28th, 2018 • Recro Pharma, Inc. • Pharmaceutical preparations • Delaware
This Second Amendment to Asset Transfer and License Agreement (this “Second Amendment”), dated December 20, 2018, entered into by and between Alkermes Pharma Ireland Limited, a private company limited by shares and incorporated in Ireland (“APIL”), and Recro Gainesville LLC (as successor to DV Technology LLC), a Massachusetts limited liability company (“Recro” or “Purchaser”), amends that certain Asset Transfer and License Agreement, dated as of April 10, 2015 and amended on December 23, 2015, by and among the parties hereto (as so amended, the “Agreement”).
FIRST AMENDMENT TO WARRANT TO PURCHASE STOCKWarrant to Purchase Stock • December 28th, 2018 • Recro Pharma, Inc. • Pharmaceutical preparations • Pennsylvania
This FIRST AMENDMENT TO WARRANT TO PURCHASE STOCK (this “Amendment”) is made as of December 20, 2018, by and among Recro Pharma, Inc., a Pennsylvania corporation (the “Company”), and Alkermes Pharma Ireland Limited, a private limited company incorporated in Ireland (together with any successor or permitted assignee or transferee of the Warrant, “Holder”) to amend that certain Warrant to Purchase Stock issued in favor of the Holder on April 10, 2015 (the “Warrant”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Warrant.
